Study of Mass General Brigham Biobank participants links treatment with reduced incidence and progression of disease.
- The growth of prenatal screening in Europe has reduced the number of babies being born per year with Down syndrome
- In research published in 2016, the same team found that 33% fewer babies with DS per year were born in the United States as a result of pregnancy terminations.
- Researchers hope studies will pave the way for governments and Down syndrome organizations to work together and share best practices on thoughtful approaches to implementing NIPS
Brian G. Skotko, MD, MPP
Without an accurate estimate, it’s impossible for policymakers and advocacy organizations to determine how many resources and support services are needed for its Down syndrome population.
Investigator, Mass General Hospital for Children
BOSTON -- The growth of prenatal screening in Europe has reduced the number of babies being born per year with Down syndrome (DS) by an average of 54%, according to a new study published in the European Journal of Human Genetics by researchers from Massachusetts General Hospital (MGH) and international Down syndrome organizations. In research published in 2016, the same team found that 33% fewer babies with DS per year were born in the United States as a result of pregnancy terminations.
The researchers spent three years collecting data from multiple registries and databases in every country in Europe to estimate the number of babies being born with DS and the overall number of people with DS in the population. “People with DS were being counted sporadically, inconsistently, or not at all, depending on the country,” says Brian G. Skotko, MD, MPP, a medical geneticist at MGH and senior author. “But without an accurate estimate, it’s impossible for policymakers and advocacy organizations to determine how many resources and support services are needed for its Down syndrome population.” The researchers applied statistical modeling to create estimates in countries where there were gaps in data. “These data are as close to accurate as possible,” says Skotko. The data are laid out in both the study and an associated fact sheet.
Equally important, however, was for the study to establish a baseline of DS birth rates and pregnancy termination rates ahead of widespread adoption of new noninvasive prenatal screenings (NIPS). The new screening tests can detect the likelihood of a chromosomal condition in a fetus as early as nine weeks of gestation, after which an expectant couple can elect to pursue definitive genetic testing. As NIPS becomes widely available, fewer babies with DS are expected to be born.
NIPS was introduced in the U.S. in 2011 but has yet to be widely covered by national health care systems in European countries. “Countries that are grappling with funding decisions for NIPS should certainly be having deep discussions about its impact on the country’s Down syndrome population,” says Skotko, who has a 40-year-old sister with DS. Countries also must create an adequate infrastructure of support and information so that expectant couples can make informed decisions about NIPS and subsequent pregnancies.
The researchers discovered a wide variation in DS birth rates among European regions. From 2011 to 2015, Southern Europe had the highest reduction in DS births due to pregnancy terminations (71%), followed by Northern Europe (51%) and Eastern Europe (38%). There were, however, considerable differences among countries, ranging from no reduction in the percentage of babies being born with DS in Malta, where pregnancy termination is highly restricted, to an 83% reduction in Spain.
Pregnancy terminations related to DS are influenced by multiple factors. Some nations, such as Denmark, provide free access to prenatal screening, whereas there may be cost barriers for couples in other countries. A country’s religious and cultural mores also play a role, as does a country’s policies about the way expectant couples are counseled about prenatal screening and DS. Parents’ decisions might also be influenced by the opportunities that exist for people with DS to live fulfilling, productive lives within a country. “In the U.S., people with Down syndrome have great opportunities to get an education, to fall in love, and to find satisfying jobs,” says Skotko.
The modeling study also estimated the number of people with DS currently living in each country. The decreasing number of DS births is offset by people with DS living longer than ever—to an average age of around 60 in countries with resource-rich health care systems. In Europe there were 27% fewer people living with DS in the overall population in 2015 (and 21% fewer people with DS in the U.S.) as a consequence of elective pregnancy termination from previous years.
Skotko and his international colleagues hope that the European and U.S. studies will pave the way for governments and DS organizations to work together and share best practices on thoughtful approaches to implementing NIPS and to supporting couples who receive a prenatal DS diagnosis. “Massachusetts, for example, has an outstanding network of parents who are willing to talk about their lived experiences of raising children with Down syndrome to expectant couples,” says Skotko. “That nonprofit has trained parent groups in Brazil, Japan and elsewhere so they don’t have to reinvent the wheel.”
The researchers are planning a similar modeling study in Australia and New Zealand, and they will continue to update each country’s data to measure the impact of different prenatal testing policies and of NIPS as it becomes more widely available. This research is unfunded; Skotko and his colleagues have volunteered their time to do these analyses. “We just feel it is so important to provide countries with accurate numbers of their citizens with Down syndrome,” says Skotko.
Brian Skotko, MD, MPP, is the Emma Campbell Endowed Chair on Down Syndrome and director of the Down Syndrome Program at MGH. Gert de Graaf, PhD, is the education and science officer of the Dutch Down Syndrome Foundation and the paper’s first author. Co-author Frank Buckley is CEO of the Down Syndrome Education International and Down Syndrome Education USA.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
Related News and Articles
- Press Release
- May | 18 | 2022
Scientists develop and monitor two approaches to fix blood vessel abnormalities that make tumors difficult to treat
Combining the approaches may be a powerful anti-cancer strategy.
- Press Release
- May | 16 | 2022
Preventing medication administration errors and improving efficiency during surgery enhances patient care.
- Press Release
- May | 13 | 2022
Clinical trial is planned based on results from preclinical study.
- Press Release
- May | 12 | 2022
The team used these models to show that several topical drugs can cause the lesions to recede. One of the topical treatments protected against cancer development.
- Press Release
- May | 5 | 2022
Starting screening before age 50 is found to significantly reduce the risk and incidence of colorectal cancer in women
A new study reports a 50 to 60 percent lower risk of colorectal cancer (CRC) among women who started endoscopy screening at age 45 compared to those who had not undergone screening at all.